A2 Biotherapeutics Closes $80 Million Series C | citybiz

A2 Biotherapeutics Closes $80 Million Series C | Citybiz

3 weeks from now

Jan 9, 2025  · AGOURA HILLS, Calif. — (BUSINESS WIRE) — A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to …

citybiz.co

A2 Biotherapeutics Closes $80 Million Series C Financing To …

3 weeks from now

Jan 9, 2025  · A2 Biotherapeutics, established in 2018, is a fully integrated discovery, development and manufacturing company based in Agoura Hills, Calif. A2 Bio plans to direct the Series C …

yahoo.com

A2 Bio Highlights Progress Of Tmod

3 weeks from now

A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Clinical Development of its Precision Cell Therapies Using its Proprietary Tmod TM Technology Platform. AGOURA …

a2bio.com

A2 Biotherapeutics Closes $80 Million Series C Financing To …

3 weeks from now

January 09, 2025 09:02 AM Eastern Standard Time. AGOURA HILLS, Calif.–(BUSINESS WIRE)–A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first …

intelligence360.news

A2 Biotherapeutics Closes $80 Million Series C Financing To

3 weeks from now

Jan 9, 2025  · AGOURA HILLS, Calif.--(BUSINESS WIRE)--A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to …

biospace.com

A2 Bio Closes $80 Million Series C Financing Round

3 weeks from now

Jan 9, 2025  · Agoura Hills-based A2 Biotherapeutics, a clinical-stage cell therapy company, on Jan. 9 announced the closing of its $80 million Series C financing round, supported by a …

pacbiztimes.com

A2 Biotherapeutics Raises $80M Series C - Citybiz

3 weeks from now

Jan 10, 2025  · A2 Biotherapeuti cs, an Agoura Hills, CA-based clinical-stage cell therapy company developing logic-gated cell therapies to selectively target tumor cells and protect …

citybiz.co

A2 Biotherapeutics Secures $80M Series C To Advance Logic …

3 weeks from now

Jan 17, 2025  · A2 Biotherapeutics, Inc., a clinical-stage company specialising in logic-gated cell therapies, has announced the successful close of an $80 million Series C financing round. The …

pharmasource.global

A2 Biotherapeutics Secures $80 Million In Series C Funding For ...

3 weeks from now

Jan 9, 2025  · A2 Biotherapeutics, Inc. successfully closes an $80 million Series C financing round, led by The Column Group and Samsara BioCapital, to advance its cell therapy …

venturecapital.com

A2 Biotherapeutics Completes $80M Series C - Vcnewsdaily.com

3 weeks from now

Jan 9, 2025  · A2 Biotherapeutics, a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect normal cells, today …

vcnewsdaily.com

A2 Biotherapeutics Closes $80 Million Series C Financing To …

3 weeks from now

Jan 9, 2025  · AGOURA HILLS, Calif. – A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor …

envzone.com

A2 Biotherapeutics: $80 Million (Series C) Raised For Advancing ...

3 weeks from now

A2 Biotherapeutics - a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to target tumor cells and protect normal cells selectively - announced the closing of …

pulse2.com

A2 Biotherapeutics Closes $80 Million Series C Financing To …

3 weeks from now

Jan 9, 2025  · A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect normal cells, …

financialcontent.com

Invest In A2 Biotherapeutics Stock | Buy Pre-IPO Shares - EquityZen

3 weeks from now

Jan 10, 2025  · Cell therapy startup A2 Biotherapeutics nets $80M Series C. endpts • Jan 10, 2025. ... 2025. A2 Biotherapeutics Closes $80 Million Series C. citybiz • Jan 10, 2025. A2 …

equityzen.com

A2 Bio Closes $80M Series C Capital Raise

3 weeks from now

Jan 17, 2025  · James Robinson, CEO of A2 Biotherapeutics. (courtesy photo) Established in 2018, Agoura Hills-based A2 Biotherapeutics is developing first-in-class logic-gated cell …

pacbiztimes.com

Series C - A2 Biotherapeutics - 2025-01-09 - Crunchbase

3 weeks from now

Jan 9, 2025  · Business Wire — A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Clinical Development of Its Precision Cell Therapies Using Its Proprietary Tmod™ …

crunchbase.com

A2 Biotherapeutics Closes $80 Million Series C Financing To …

3 weeks from now

On January 9, 2025 A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect …

1stoncology.com

A2 Biotherapeutics Closes $80 Million Series C Financing To

3 weeks from now

Jan 9, 2025  · A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Clinical Development of Its Precision Cell Therapies Using Its Proprietary Tmod™ Technology Platform

advfn.com